[Temporary Announcement] Anbang Pharmaceutical: Announcement on adjusting the organizational structure, canceling independent directors, special committees of the board of directors and related work systems

Announcement number: 2026-027

Securities code: 874011 Securities abbreviation: Anbang Pharmaceutical Sponsored broker: Caixin Securities

Hunan Anbang Pharmaceutical Co., Ltd.

Regarding adjustments to the organizational structure, elimination of independent directors, special committees of the board of directors and

Announcements on relevant work systems

The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions, and bear individual and joint legal liability for the authenticity, accuracy and completeness of the contents.

1. Basic situation

Hunan Anbang Pharmaceutical Co., Ltd. (hereinafter referred to as "Anbang Pharmaceutical" or the "Company") held the 14th meeting of the company's second board of directors on September 29, 2026, and reviewed and approved the "Proposal on Adjusting the Organizational Structure, Abolition of Independent Directors, Special Committees of the Board of Directors and Related Working Systems".

In accordance with relevant regulations such as the Company Law, the Measures for the Supervision and Administration of Non-Listed Public Companies, the Governance Rules for Companies Listed on the National Equities Exchange and Quotations, and in combination with the company's strategic planning and the actual situation of current operational governance, the company plans to adjust the board of directors and the company's internal organizational structure, cancel the establishment of independent directors, cancel the board strategy committee, nomination committee, and remuneration and assessment committee established as stated in the original Articles of Association, and adjust the number of board members from 7 to 5. The "Working System of Independent Directors", "Rules of Procedure of the Strategy Committee", "Rules of Procedure of the Nomination Committee" and "Rules of Procedure of the Remuneration and Appraisal Committee" are abolished, and the provisions related to matters related to independent directors and the above-mentioned special committees in the "Articles of Association" and other system rules of the company are abolished simultaneously.

The adjusted internal organizational structure of the company is as follows:

Announcement number: 2026-027

2. Deliberation and voting

The company's 14th meeting of the second board of directors held on September 29, 2026, reviewed and approved the "Proposal on Adjusting the Organizational Structure, Abolition of Independent Directors, Special Committees of the Board of Directors and Related Work Systems". The company's independent directors Peng Shuqiao, Shi Zhangqiang, and Yang Xiaojun expressed their independent opinions in agreement on this matter. This proposal still needs to be submitted to the shareholders' meeting for review.

3. Impact on the company

This adjustment of corporate governance and internal organizational structure based on the company's actual situation will help further optimize the company's governance structure and internal processes, improve the company's overall operational management efficiency, promote the company's steady development, and meet the company's actual development needs.

4. Documents for reference

"Resolution of the 14th Meeting of the Second Board of Directors of Hunan Anbang Pharmaceutical Co., Ltd."

Board of Directors of Hunan Anbang Pharmaceutical Co., Ltd.

September 30, 2026